TY - JOUR
T1 - The MG-QOL15 Japanese version
T2 - Validation and associations with clinical factors
AU - Masuda, Masayuki
AU - Utsugisawa, Kimiaki
AU - Suzuki, Shigeaki
AU - Nagane, Yuriko
AU - Ito, Suguru
AU - Kabasawa, Chiaki
AU - Suzuki, Yasushi
AU - Shimizu, Yuko
AU - Utsumi, Hiroya
AU - Fujihara, Kazuo
AU - Uchiyama, Shinichiro
AU - Suzuki, Norihiro
PY - 2012
Y1 - 2012
N2 - We produced a Japanese translation of the 15-item myasthenia gravis (MG)-specific quality of life (QOL) scale (MG-QOL15), assessed its reliability and validity, and examined clinical factors affecting the self-perceived QOL in MG. Consecutive 327 patients with MG seen at six neurological centers were evaluated. All patients completed an MG-QOL15 Japanese version (MG-QOL15-J), the Beck Depression Inventory-Second Edition (BDI-II), and a generic health-related QOL questionnaire, the SF-36. Disease severity was determined according to the MG Foundation of America (MGFA) quantitative MG score and the MG composite. The MG-QOL15-J exhibited adequate internal reliability, test-retest repeatability, and concurrent validity with SF-36, disease severity, and known-patient groups categorized by MGFA postintervention status. Multivariate analysis revealed severity, dose of oral corticosteroids, and BDI-II as independent factors negatively affecting QOL. The MG-QOL15-J is anticipated to be a valuable clinical measure of QOL in Japanese patients with MG.
AB - We produced a Japanese translation of the 15-item myasthenia gravis (MG)-specific quality of life (QOL) scale (MG-QOL15), assessed its reliability and validity, and examined clinical factors affecting the self-perceived QOL in MG. Consecutive 327 patients with MG seen at six neurological centers were evaluated. All patients completed an MG-QOL15 Japanese version (MG-QOL15-J), the Beck Depression Inventory-Second Edition (BDI-II), and a generic health-related QOL questionnaire, the SF-36. Disease severity was determined according to the MG Foundation of America (MGFA) quantitative MG score and the MG composite. The MG-QOL15-J exhibited adequate internal reliability, test-retest repeatability, and concurrent validity with SF-36, disease severity, and known-patient groups categorized by MGFA postintervention status. Multivariate analysis revealed severity, dose of oral corticosteroids, and BDI-II as independent factors negatively affecting QOL. The MG-QOL15-J is anticipated to be a valuable clinical measure of QOL in Japanese patients with MG.
KW - Cross-sectional study
KW - Health-related quality of life
KW - Myasthenia gravis
KW - Questionnaire
KW - Validity
UR - http://www.scopus.com/inward/record.url?scp=84880541452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880541452&partnerID=8YFLogxK
U2 - 10.5692/clinicalneurol.52.1043
DO - 10.5692/clinicalneurol.52.1043
M3 - Article
C2 - 23196510
AN - SCOPUS:84880541452
SN - 0009-918X
VL - 52
SP - 1043
EP - 1046
JO - Clinical Neurology
JF - Clinical Neurology
IS - 11
ER -